<DOC>
	<DOCNO>NCT01099904</DOCNO>
	<brief_summary>This open-label , parallel group study evaluate effect renal function pharmacokinetics RO4995855 follow multiple oral dose administration RO5024048 assess effect renal impairment safety tolerability RO5024048 . Adult males female either normal renal function mild moderate renal impairment receive RO5024048 orally 5 day . Target sample size &lt; 50 .</brief_summary>
	<brief_title>A Study Effect Renal Function Pharmacakokinetics RO5024048 ( Parent Prodrug RO5024048 ) Following Multiple Oral Dose Administration RO5024048</brief_title>
	<detailed_description />
	<criteria>male female adult , 1875 year age normal , mildly moderately impaired renal function ( creatinine clearance &gt; /= 30 mL/min ) BMI 1840 kg/m2 stable renal function agree abstain alcohol consumption study drug adminsitration limit consumption end study agree abstain coffein consumption throughout study positive urine blood test drug abuse physician 's prescription positive HIV HCV , HBV clinical symptom history hepatitis uncontrolled hypertension renal transplant , dialysis patient , nephritic syndrome clinically significant cardiovascular , central nervous system , gastrointestinal liver disease disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>